{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:53:43Z","timestamp":1787014423928,"version":"build-2736575974"},"reference-count":54,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1633,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1111\/j.1365-2036.2011.04627.x","type":"journal-article","created":{"date-parts":[[2011,3,13]],"date-time":"2011-03-13T20:53:13Z","timestamp":1300049593000},"page":"1087-1103","source":"Crossref","is-referenced-by-count":64,"title":["Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis"],"prefix":"10.1111","volume":"33","author":[{"given":"X.","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,13]]},"reference":[{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11739-010-0413-6","article-title":"Splanchnic vein thrombosis: clinical presentation, risk factors and treatment","volume":"5","author":"De Stefano","year":"2010","journal-title":"Intern Emerg Med"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/hep.22772","article-title":"Vascular disorders of the liver","volume":"49","author":"DeLeve","year":"2009","journal-title":"Hepatology"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/0016-5085(88)90567-7","article-title":"Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders","volume":"94","author":"Valla","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-103-3-329","article-title":"Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome","volume":"103","author":"Valla","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2141.2005.05490.x","article-title":"Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis","volume":"129","author":"Chait","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/s-2006-939432","article-title":"Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management","volume":"32","author":"Briere","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/j.seminhematol.2005.05.020","article-title":"Bone marrow histopathology in myeloproliferative disorders - current diagnostic approach","volume":"42","author":"Thiele","year":"2005","journal-title":"Semin Hematol"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.beha.2005.07.015","article-title":"Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl","volume":"19","author":"Thiele","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/hep.21601","article-title":"High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis","volume":"45","author":"De Stefano","year":"2007","journal-title":"Hepatology"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2036.2010.04546.x","article-title":"JAK2V617F mutation and myeloproliferative disorders in splanchnic vein thrombosis: authors\u2019 reply","volume":"33","author":"Westbrook","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2036.2010.04533.x","article-title":"JAK2V617F mutation and myeloproliferative disorders in splanchnic vein thrombosis","volume":"33","author":"Qi","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/hep.21435","article-title":"Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis","volume":"44","author":"Primignani","year":"2006","journal-title":"Hepatology"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000320171","article-title":"Prevalence of the JAK2 V617F and MPL mutations in stroke, abdominal and peripheral venous thrombosis","volume":"124","author":"McCarthy","year":"2010","journal-title":"Acta Haematol"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/j.1365-2036.2010.04299.x","article-title":"The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis","volume":"31","author":"Orr","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1309\/AJCP7VO4HAIZYATP","article-title":"JAK2 mutations across a spectrum of venous thrombosis cases","volume":"134","author":"Shetty","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB24|cit24","first-page":"108","article-title":"Budd Chiari syndrome and V617F\/JAK 2 mutation linked with the myeloproliferative disorders","volume":"19","author":"Smira","year":"2010","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/hep.23259","article-title":"Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study","volume":"51","author":"Plessier","year":"2010","journal-title":"Hepatology"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1007\/s10620-009-0933-y","article-title":"JAK2V617F mutation in patients with splanchnic vein thrombosis","volume":"55","author":"Xavier","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1160\/TH08-07-0451","article-title":"Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study","volume":"101","author":"Tondeur","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-151-3-200908040-00004","article-title":"Etiology, management, and outcome of the Budd-Chiari syndrome","volume":"151","author":"Darwish Murad","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1751-553X.2007.00973.x","article-title":"The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis","volume":"30","author":"Goulding","year":"2008","journal-title":"Int J Lab Hematol"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MBC.0b013e3283049662","article-title":"Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome","volume":"19","author":"Colaizzo","year":"2008","journal-title":"Blood Coagul Fibrinol"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1007\/s10620-008-0225-y","article-title":"JAK2V617F mutation in patients with portal vein thrombosis","volume":"53","author":"Bayraktar","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MEG.0b013e3282f1cff7","article-title":"Janus kinase-2 mutation, cirrhosis and splanchnic vein thrombosis","volume":"20","author":"Colaizzo","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","article-title":"The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases","volume":"111","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1538-7836.2007.02384.x","article-title":"JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis","volume":"5","author":"Regina","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/jmg.2006.048371","article-title":"Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings","volume":"44","author":"Colaizzo","year":"2007","journal-title":"J Med Genet"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1538-7836.2007.02424.x","article-title":"Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders","volume":"5","author":"De Stefano","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1538-7836.2006.02277.x","article-title":"The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis","volume":"5","author":"Colaizzo","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1309\/JA1WD8JNVLGYNQYE","article-title":"JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses","volume":"127","author":"McMahon","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB39|cit39","first-page":"1712","article-title":"Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome","volume":"91","author":"Smalberg","year":"2006","journal-title":"Haematologica"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1182\/blood-2006-05-021527","article-title":"Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis","volume":"108","author":"Boissinot","year":"2006","journal-title":"Blood"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1600-0609.2006.00715.x","article-title":"Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications","volume":"77","author":"Gangat","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1053\/j.gastro.2006.04.008","article-title":"Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome","volume":"130","author":"Patel","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1160\/TH07-09-0570","article-title":"Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation","volume":"99","author":"Grandone","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ibd.20471","article-title":"JAK2 V617F mutation is not involved in thromboembolism in IBD","volume":"14","author":"Karimi","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ajh.21159","article-title":"Clinical JAK2V617F mutation testing: limited utility for general hospital patients with venous and arterial thromboses in common locations","volume":"83","author":"Abel","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1179\/102453308X316077","article-title":"Primary thrombophilia in Mexico VII: the V617F mutation of JAK2 is not a frequent cause of thrombosis","volume":"13","author":"Garces-Eisele","year":"2008","journal-title":"Hematology"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1365-2141.2007.06715.x","article-title":"JAK2V617F in idiopathic venous thromboembolism occurring in the absence of inherited or acquired thrombophilia","volume":"138","author":"Rossi","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1182\/blood-2008-12-196014","article-title":"JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis","volume":"113","author":"Dentali","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.21489","article-title":"JAK2 mutation: the best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis?","volume":"44","author":"Janssen","year":"2006","journal-title":"Hepatology"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1182\/blood-2008-02-139014","article-title":"JAK2V617F: better diagnostic tool than marrow?","volume":"111","author":"Kwaan","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-2007-996117","article-title":"Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis","volume":"23","author":"De Stefano","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jhep.2009.03.013","article-title":"Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development","volume":"51","author":"Zocco","year":"2009","journal-title":"J Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2036.2011.04627.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.1111\/j.1440-1746.2004.03642.x","article-title":"Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West","volume":"19","author":"Valla","year":"2004","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2011.04627.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2036.2011.04627.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T17:38:41Z","timestamp":1625420321000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2011.04627.x"}},"subtitle":["Meta-analysis: JAK2V617F mutation in BCS and PVST"],"short-title":[],"issued":{"date-parts":[[2011,3,13]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,5]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04627.x","relation":{},"ISSN":["0269-2813"],"issn-type":[{"value":"0269-2813","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,13]]}}}